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Abstract
Background: Molecular mechanisms leading to the adaptation of breast cancer (BC) cells to hypoxia are largely
unknown. The anti-apoptotic Bcl-2 family member myeloid cell leukemia-1 (Mcl-1) is frequently amplified in BC; and
elevated Mcl-1 levels have been correlated with poor prognosis. Here we investigated the pathophysiologic role of
Mcl-1 in Her2-positive BC cells under hypoxic conditions.
Methods: RNA interference and a novel small molecule inhibitor, EU-5346, were used to examine the role of Mcl-1
in Her2-positive BC cell lines and primary BC cells (sensitive or intrinsically resistant to Her2 inhibitors) under
hypoxic conditions (using a hypoxic incubation chamber). Mechanisms-of-action were investigated by RT-PCR,
mitochondrial isolation, as well as immunoprecipitation/blotting analysis, and microscopy. The specificity against Mcl-1
of the novel small molecule inhibitor EU5346 was verified in Mcl-1Δ/nullversus Mcl-1wt/wt Murine Embryonic Fibroblasts
(MEFs). Proliferation, survival, and spheroid formation were assessed in response to Mcl-1 and Her2 inhibition.
Results: We demonstrate for a strong correlation between high Mcl-1 protein levels and hypoxia, predominantly in
Her2-positive BC cells. Surprisingly, genetic depletion of Mcl-1 decreased Her2 and Hif-1α levels followed by inhibition
of BC cell survival. In contrast, Mcl-1 protein levels were not downregulated after genetic depletion of Her2 indicating a
regulatory role of Mcl-1 upstream of Her2. Indeed, Mcl-1 and Her2 co-localize within the mitochondrial fraction and
form a Mcl-1/Her2- protein complex. Similar to genetically targeting Mcl-1 the novel small molecule Mcl-1 inhibitor
EU-5346 induced cell death and decreased spheroid formation in Her2-positive BC cells. Of interest, EU-5346 induced
ubiquitination of Mcl-1- bound Her2 demonstrating a previously unknown role for Mcl-1 to stabilize Her2 protein
levels. Importantly, targeting Mcl-1 was also active in Her2-positive BC cells resistant to Her2 inhibitors, including a
brain-primed Her2-positive cell line.
Conclusion: Our data demonstrate a critical role of Mcl-1 in Her2-positive BC cell survival under hypoxic conditions
and provide the preclinical framework for the therapeutic use of novel Mcl-1- targeting agents to improve patient
outcome in BC.
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Background
Breast cancer (BC) is the most common malignancy and
the second most common cause of cancer-related mor-
tality in women. The clinically relevant classification of
BC is based on its histopathological appearance, tumor
grade, lymph node involvement, and immunohistochemi-
cal properties including the presence of the estrogen recep-
tor (ER), the progesterone receptor (PR), human epidermal
growth factor receptor 2 (Her2; ErbB2, c-erbB2), and Ki-67
[1, 2]. Importantly, BC is known to be highly heterogenic
with different intrinsic molecular subtypes. An additional
BC classification based on molecular signatures has been
developed recently with a clinical impact not only for pa-
tients’ prognosis but also the choice of treatment. Gene ex-
pression profiling has been utilized to classify BC into four
different groups [3–6]. Specifically, BC is subgrouped into
Luminal A, Luminal B, Her2-enriched, and basal-like BC
[4]. Luminal-A BC, the most common subtype, is ER-
positive and is characterized by the absence of Her2 ex-
pression, a low rate of proliferation (Ki67), and histologi-
cally low-grade tumors. Moreover, Luminal-A BC presents
with high expression in mRNA and protein levels of
the Luminal expression signature (e.g., ESR1, GATA3,
FOXA1, XBP1, and MYB) [5, 7]. Luminal-B BC includes
ER-positive but also ER-negative histologically high-grade
tumors. In contrast to Luminal A, Luminal-B BC has an in-
creased expression not only of proliferation genes such as
KI67 and cyclin B1 but also frequently overexpresses epi-
dermal growth factor receptor (EGFR) and HER2 [7].
Basal-like BC or triple-negative breast cancer (TNBC) is
characterized by ER-negative, PR-negative, and Her2-
negative tumors with high frequency of TP53 (80 %) and
PIK3CA (9 %) mutation [5]. Her2-positive (Her2-enriched)
BC is characterized by the amplification of the HER2 gene
and other genes of the HER2 amplicon including
STARD3 and GRB7 [6, 8]. Her2 in particular acts as a
coreceptor and enhances signaling pathways of other Her
family members. It is activated by homodimerization with
Her2 or heterodimerization with other Her family mem-
bers. Importantly, the heterodimer between Her2 and
Her3 has the highest mitogenic potential [9]. Overexpres-
sion of Her2 occurs in 15–20 % of BC patients and is as-
sociated with worse biologic behavior; that is, increased
rate of metastasis, and poor clinical outcome without
Her2-targeted treatment [10]. Unprecedented therapeutic
advances have been achieved during the last years by com-
bining Her2 inhibitors trastuzumab (Herceptin®, Genen-
tech, South San Francisco, CA, USA), lapatinib (Tykerb®,
GlaxoSmithKline, Philadelphia, PA, USA; Tyverb®, Glax-
oSmithKline, London, UK), and pertuzumab (Perjeta®,
Genentech, South San Francisco, CA, USA) with chemo-
therapeutic regimens, and by the introduction of ado-
trastuzumab emtansine (T-DM1, Kadcyla®, Genentech,
South San Francisco, CA, USA) monotherapy. However,
inherent and acquired resistance to these agents remains a
significant barrier to further reduce mortality in this BC
patient subtype, highlighting the urgent need for novel
therapies [11]. In addition, these drugs do not penetrate
the blood–brain barrier as easily as they reach the rest of
the body, with lapatinib in combination with capecitabine
and T-DM1 monotherapy being a possible exception [12].
Hypoxic conditions develop during cancer progression
because of rapidly proliferating tumor cells that reduce
oxygen diffusion and impair perfusion of abnormal blood
vessels in the tumor microenvironment. Cellular adaptation
to hypoxia is predominantly mediated through protein
stabilization of hypoxia-inducible factor (Hif) subunits. In
BC, hypoxic regions have the potential to confer chemo-
therapy and radiation therapy resistance [13]. Molecular
mechanisms which lead to the adaptation of BC cells to
hypoxia are largely unknown.
Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic pro-
tein of the Bcl-2 family characterized by its ability to oppose
several apoptotic stimuli, a short half-life, its wide intracel-
lular localization, and multiple pathways which tightly regu-
late Mcl-1 transcription, translation, and degradation [14].
Structurally, the N-terminus differs from the other anti-
apoptotic Bcl-2 proteins in that it contains two polypeptide
sequences enriched in proline, glutamic acid, serine, and
threonine (PEST) [15]. PEST regions are made responsible
for Mcl-1 degradation via the proteasome pathway,
localization, and phosphorylation, thus providing the mech-
anistic base for the fine-tuned Mcl-1 protein functions in
response to environmental stimuli and the cellular origin
[14, 16, 17]. The pro-survival function of Mcl-1 is predom-
inantly mediated by its binding to Bak and Bim. Conversely,
release of Bak or Bim from their interaction with Mcl-1 in-
duces apoptosis [18]. In addition, binding to the Bcl-2 hom-
ology 3 (BH3)-only protein NOXA enhances Mcl-1
degradation followed by caspase activation. In contrast,
blockade of NOXA induction results in the suppression of
apoptosis [19, 20]. Several past studies indicated that Mcl-1
is an important cancer target. Specifically, Mcl-1 is ampli-
fied in many cancers including BC and elevated Mcl-1
levels in BC correlate with increased tumor cell survival,
growth, and poor prognosis [21–23]. Both epidermal
growth factor and estrogen induce Mcl-1 expression via
binding to their respective receptors and activation of
downstream signaling pathways [24, 25]. Importantly,
Mcl-1 mediates resistance against widely used anticancer
therapies including paclitaxel [26] and gemcitabine
[27] as well as early clinical BH3 mimetic drugs that
block Bcl-2 and Bcl-xL [21, 28]. Moreover, trastuzumab
sensitizes Her2-overexpressing cells to apoptosis by redu-
cing anti-apoptotic Mcl-1 expression [29]. Based on these
data, Mcl-1 holds great promise as a high-priority
therapeutic target. Indeed, Mcl-1 is the current focus
of widespread cancer drug development efforts, and a
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number of Mcl-1 inhibitors are in the cancer drug develop-
ment pipeline worldwide [30].
In this study we determined a critical role of Mcl-1 in
Her2-positive BC cell survival under hypoxic conditions
also including brain-primed BC cells, and we present
EU-5346 as a promising novel anti-Mcl-1 targeting
agent. We thereby provide the preclinical framework for
the therapeutic use of novel Mcl-1-targeting agents to
improve patient outcome in BC.
Methods
Materials
Lapatinib ditosylate and ABT-199 were purchased from
Santa Cruz Biotechnology (Heidelberg, Germany); cobalt
(II) chloride hexahydrate from Sigma Aldrich (Schnelldorf,
Germany); trastuzumab (Herceptin®) from Roche (San
Francisco, CA, USA); and ZVAD pan-caspase inhibitor
z-VAD-fmk from Bachem (Bubendorf, Switzerland).
Antibodies against human Mcl-1 (S-19), extracellular
signal-regulated kinase 2 (ERK2), and Ubiquitin (P4D1)
were obtained from Santa Cruz Biotechnology; anti-
bodies against Her2/ErbB2 (D8F12), Poly (ADP-ribose)
polymerase (PARP), Bcl-xL, and Prohibitin-1 from Cell Sig-
naling Technology (Boston, MA, USA); the antibody
against α-tubulin from Sigma Aldrich; the antibody against
Hif-1α, EpCAM, and ErbB2/Her2 from BD Biosciences
(Heidelberg, Germany); the antibody against Bcl-2
(ab18210) from Abcam (Boston, MA, USA); and the anti-
body against murine Mcl-1 from Rockland Immuno-
chemicals Inc., Limerick, PA 19468, USA.
Isolation of primary tumor cells
BC cells were collected by centrifugation of pleural fluid.
The cell pellet was resuspended with RPMI medium and
placed in culture flasks; >95 % purity of BC cells was con-
firmed using anti-EpCAM and anti-Her2 antibodies by
fluorescence-activated cell sorting (FACS) analysis. Sam-
ples were isolated from patients with advanced disease
and resistant against multiple agents including hormone
therapy, Her2 inhibitors, capecitabine, paclitaxel, eribulin,
and everolimus. The collection and use of patient BC cells
has been approved by the ethics committee of the Medical
Faculty, University of Heidelberg (approval number 022/
2013). Informed consent was obtained in accordance with
the Declaration of Helsinki.
Cell culture and conditions
MCF-7 cells were a kind gift from Dr Beckhove
(German Cancer Research Center (DKFZ), Heidelberg,
Germany), MDA MB-157 and MDA MB-468 cells were
from Dr Oskarsson (DKFZ), HCC-1954 and MCF-10A
cells were from Dr Wiemann (DKFZ), and SKBR3 cells
were from Dr Trumpp (DKFZ). JIMT-1-BR3 cells (brain
metastatic BC cell line) were a kind gift from Dr Steeg
(Laboratory of Molecular Pharmacology, NCI’s Women's
Malignancies Branch, National Cancer Institute/National
Institutes of Health, Bethesda, MD, USA). JIMT-1-BR3
cells were obtained by a method detailed in previous pub-
lication [31]. All other cell lines were purchased from the
Leibniz Institute DSMZ—German Collection of Microor-
ganisms and Cell Cultures (Braunschweig, Germany).
MCF-7, MDA MB 231, and HCC-1954 cells were cultured
in RPMI 1640 medium (Gibco, Life Technologies,
Grand Island, NY, USA) supplemented with 10 % heat-
inactivated fetal bovine serum (FBS; PAA Laboratories,
Cölbe, Germany), 1 % penicillin/streptomycin and 2 mM
L-glutamine (all from Gibco, Life Technologies). MDA
MB 453, MDA MB-157, MDA MB-468, JIMT-1, and
JIMT-1 BR3 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, Life Technologies) sup-
plemented with 10 % heat-inactivated FBS, 1 % penicillin/
streptomycin and 2 mML-glutamine. BT-474 and SKBR3
cells were maintained similarly to MDA MB 453 cells, but
with the addition of minimum essential medium (MEM)
nonessential amino acids (Gibco, Life Technologies).
MCF-10A cells were maintained in DMEM/F12 supple-
mented with 10 % heat-inactivated FBS, 1 % penicillin/
streptomycin, 2.5 mg insulin, 5 mg hydrocortisone
(Sigma), 8 μl cholera toxin, and 10 μg human epidermal
growth factor (Sigma Aldrich). Murine embryonic
fibroblast (MEF) cell lines Mcl-1wt/wt and Mcl-1Δ/null-
were generated by SV40 large T transformation followed
by Tet-Cre-mediated deletion. Single cell clones were se-
lected and then grown in DMEM supplemented with
10 % heat-inactivated FBS, 1 % penicillin/streptomycin,
2 mML-glutamine, 2-mercaptoethanol (Sigma Aldrich),
and MEM nonessential amino acids (Gibco, Life Tech-
nologies) from early passages. Both Mcl-1wt/wt and
Mcl-1Δ/null MEFs were extensively characterized as
being hypersensitive to various death stimuli with restor-
able resistance upon re-expression of Mcl-1 [32]. For hyp-
oxia, cells were incubated in a hypoxia chamber (COY
Laboratory Products, Ann Arbor, MI, USA) with a com-
puterized oxygen controller to maintain an atmosphere of
0.5– 1 % oxygen, 5 % carbon dioxide, and 37 °C.
Small interfering RNAs and cell transfection
BC cells were transiently transfected with indicated
amounts of small interfering RNA (siRNA) siGENOME
SMART pools of MCL1 (4170) and HER2 (2064), or the
nontargeting control (mock) siRNA (Upstate Cell Signaling
Solutions/Dharmacon RNA Technologies, Lafayette, CO,
USA) using Lipofectamine® 2000 according to the manu-
facturer's instructions (Invitrogen, Darmstadt, Germany).
Nontargeting control (mock) siRNA is composed of a
pool of four siRNAs, which have been characterized
by genome-wide microarray analysis and found to have
minimal off-target signatures.
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Cell death assays
The inhibitory effect of hypoxia, siMCL1, or siHER2 on
BC cell lines was assessed using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma
Aldrich) as described previously [33], or AlamarBlue® assay
(Invitrogen) according to the manufacturer's instructions.
Cell lysis, immunoblotting, and immunoprecipitation
Treated or untreated cells were washed three times with
phosphate-buffered saline and lysed with either lysis buf-
fer (10 mm Tris, 50 mm NaCl, 1 % Triton, 30 mM sodium
pyrophosphate, pH 7.05) or radioimmune precipitation
assay lysis buffer (150 mM NaCl, 10 mM Tris, pH 7.2,
0.1 % SDS, 1 % Triton X-100, 1 % deoxycholate, 5 mM
ethylenediamine tetraacetic acid) supplemented with Halt
Protease and Phosphatase Inhibitor Cocktail (Pierce,
Darmstadt, Germany). Insoluble material was removed by
centrifugation (15,000 rpm for 30 minutes at 4 °C). Immu-
nocomplexes were collected following overnight incuba-
tion at 4 °C with 10–20 μl of 100 % protein A-Sepharose®
CL-4B beads (Amersham, Arlington Heights, USA). For
western blotting, cell lysates (10–100 μg/lane) or immuno-
precipitates (300–700 μg total proteins) were separated by
8 or 10 % SDS-PAGE prior to electrophoretic transfer onto
Hybond™-C super nitrocellulose membranes (Amersham).
After blocking with 5 % nonfat milk in phosphate-buffered
saline-Tween®20 buffer at room temperature for 1 hour,
membranes were sequentially blotted with the indicated
specific primary antibodies and then with horseradish per-
oxidase-conjugated secondary mouse or rabbit Abs (Santa
Cruz Biotechnology (Heidelberg, Germany)) and were de-
veloped using chemiluminescence (Amersham, Arlington
Heights, USA) [33].
Reverse transcription PCR
Reverse transcription PCR was performed as described
previously [34]. Specifically, total RNA was purified
with the RNeasy® Mini Kit (Qiagen, Hilden, Germany),
according to the manufacturer's instructions, and then
reverse transcribed and synthesized to cDNA using
Omniscript® reverse transcriptase (Qiagen). PCR ampli-
fication was performed using Taq DNA polymerase
(Qiagen). The primers used to amplify human MCL1
were 5′-ATCTCTCGGTACCTTCGGGAGC-3′ (sense)
and 5′-CCTGATGCCACCTTCTAGGTCC-3′ (antisense).
The primers for human β-ACTIN were 5′-CTGGGACGA
CATGGAGAAAA-3′ (sense) and 5′-AAGGAAGGCTG-
GAAGAGTGC-3′ (antisense). The thermal cycle profile
consisted of denaturing at 94 °C for 45 seconds, annealing
at 60 °C for 45 seconds, and extension at 72 °C for 40 sec-
onds. The samples were amplified for 30 cycles. We used 8
pmol of primers. The integrity of mRNA of all samples
was confirmed by amplification of β-actin. PCR products
were separated on a 1 % agarose gel and photographed.
Mitochondrial isolation
Extracts of cytoplasmic and mitochondrial fractions were
prepared using the Qproteome Mitochondria Isolation Kit
(Qiagen), according to the manufacturer’s instructions.
Proliferation assay
Proliferation was measured by the incorporation of
0.5 μCi/well [3H]-thymidine (Perkin Elmer, Baesweiler,
Germany) during the last 8 hours of 72-hour experi-
ments. Radioactive labeling was determined by harvest-
ing the cells onto glass-fiber filtermates (Perkin Elmer)
with an automatic cell harvester (Harvester 96, Tomtec
Inc., Hamden, CT, USA) and counting using the Wallac
Trilux Betaplate scintillation counter (Perkin Elmer).
Annexin V apoptosis detection
Cells were treated as indicated, then washed with
phosphate-buffered saline and costained with fluorescein
isothiocyanate (FITC)-labeled Annexin V and propidium
iodide (PI) using the FITC Annexin V Apoptosis Detection
Kit I (BD Pharmingen, San Diego, CA, USA) following the
manufacturer’s instructions. Apoptosis was analyzed on a
FACS Canto II flow cytometer (BD Biosciences).
Spheroid formation assay
Single multicellular BC spheroids were formed as
described previously [35]. Briefly, 4 × 103–6 × 103 BC
cells were seeded on agarose-coated (Sigma Aldrich,
Steinheim, Germany) 96-well plates. At the end of the
experiments, spheroids were stained with Calcein AM
(green) (Sigma Aldrich, Steinheim) and PI (red) (Sigma
Aldrich, Steinheim). For image capturing, the Olympus
CKX41 microscope using 4× and 10× magnification was
connected to an Olympus XC30 digital camera and
exported to the cellSens standard software (version 1.4)
(Olympus Corporation, Shinjuku, Tokyo, Japan). Based
on the automatic measurement of the radius, volumes of
the spheroids were calculated (V = 4/3 πr3).
Isobologram analysis
The interaction between EU-5346 and trastuzumab was
analyzed using the CompuSyn software program (Com-
boSyn, Inc., http://www.combosyn.com/), which is based
on the Chou-Talalay method [36]. When combination
index (CI) = 1, this equation represents the conservation
isobologram and indicates an additive effect. CI <1 indi-
cates synergism; CI >1 indicates antagonism.
Statistical analysis
Statistical significance of differences observed in treated
versus control cultures was determined by means of an un-
paired Student t test. Statistical analyses were performed
using SigmaPlot version 12.5 software (Systat Software
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GmbH, D-40699 Erkrath, Germany). The minimal level of
significance was p <0.05.
Results
Mcl-1 expression correlates with improved adaptation of
Her2-positive BC cell lines to hypoxia
Given the prognostic adverse role of hypoxia in BC, we
first evaluated whether there are differences in the adap-
tation between cell lines representing different BC sub-
types [37, 38] to hypoxia. Our results demonstrate
improved adaptation of Her2-positive BC cells (BT-474,
HCC-1954, JIMT-1) versus TNBC (MDA MB 231, MDA
MB-468, MDA MB-157), Her2-negative cells (MCF-7),
and a nonmalignant breast cell line (MCF-10A) to
hypoxic conditions utilizing both MTT (Fig. 1a) and
[3H]-thymidine uptake assays (data not shown). Previous
studies have indicated a key role of the Bcl-2 family of
anti-apoptotic proteins, and Mcl-1 in particular, in BC
cell survival. Indeed, Her2 and Mcl-1 expression corre-
lates in BC cells under normoxic conditions [29].
Whether Mcl-1 contributes to the adaptation of BC cells
to hypoxia in general, and Her2-positive BC cells in par-
ticular, is currently unknown. Our results show consist-
ently high Mcl-1, but variable Bcl-2 and Bcl-xL protein
levels in a cell line panel of different BC subtypes, in-
cluding Luminal A-like (MCF-7), Luminal B-like/Her2-
positive (BT-474), Her2-positive (HCC-1954, SKBR3),
and TNBC cells (MDA MB-231) [37, 38] under hypoxic
Fig. 1 Mcl-1 expression correlates with improved adaptation of Her2-positive BC cell lines to hypoxia. a Improved adaptation to hypoxic conditions of
Her2-positive versus Her2-negative BC cells and the benign MCF-10A cell line. BC cell lines were incubated under hypoxic conditions for the time
periods indicated. Cell survival was analyzed by MTT assay. Data represent mean ± SD for triplicate samples. Results shown are representative of three
independent experiments. b Significant protein levels of Mcl-1, but not Bcl-2 or Bcl-xL, in BC cells under hypoxic conditions. BC cell lines or
the nonmalignant MCF-10A cells were incubated for 4 hours under hypoxic conditions and whole-cell extracts were analyzed by immunoblotting
with indicated antibodies. Immunoblotting for Erk2 confirmed equal protein loading. c Upregulation of Mcl-1 in Her2-positive BC cells under hypoxic
conditions. BC cell lines were incubated under hypoxic conditions for up to 24 hours. Whole-cell extracts were analyzed by immunoblotting with
indicated antibodies. Immunoblotting for Erk2 confirmed equal protein loading. Densitometric measurements (NIH ImageJ software) [59]
were used to quantitate Mcl-1 protein levels from western blot images normalized for Erk2. Densitometric data represent mean values ± SD. Data
shown are representative of three independent experiments. C normoxic control, Erk2 extracellular signal-regulated kinase 2, Her2 human epidermal
growth factor receptor 2, Hif hypoxia-inducible factor, Mcl-1 myeloid cell leukemia-1
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conditions (Fig. 1b). In contrast, Mcl-1 protein levels
were low in the benign MCF-10A BC cell line. More-
over, Mcl-1 protein levels of BC exposed to hypoxia
were transiently increased 2.41-fold (standard deviation
(SD) ±0.44), 2.57-fold (SD ±0.34), and 3.31-fold (SD
±0.31) in Her2-positive BT474, SKBR3, and HCC-1954
BC cells, respectively. Increases in Mcl-1 protein levels
correlated with increases in protein levels of Hif-1α
(Fig. 1c). To determine whether changes in Mcl-1 pro-
tein levels were due to elevated transcription or post-
transcriptional regulation, we next detected MCL1
mRNA levels over a period of 24 hours using semiquantita-
tive reverse transcription PCR. Our results show that
mRNA levels of MCL1 did not change over time, indicat-
ing a transient hypoxia-mediated increase in Mcl-1 stability
(Additional file 1: Figure S1). Taken together, these data
suggest a role for Mcl-1 in BC cell adaptation to hypoxia in
general, and Her2-positive BC cells in particular.
Mcl-1 is an upstream regulator of Her2 under hypoxic
conditions
To evaluate a potential functional interrelation of Mcl-1
and Her2 in Her2-positive BC cells under hypoxic con-
ditions, we next transfected the Her2-positive BC cell
lines BT-474 and SKBR3 with a pool of siRNA directed
against the MCL1 gene (siMCL1) and tested for both
Her2 and Hif-1α protein levels. Our data demonstrate
marked downregulation of Her2 and Hif-1α in Her2-
positive BC cells depleted of Mcl-1. Moreover, silencing
of MCL1 induced cell death as evidenced by PARP cleav-
age (Fig. 2a). Surprisingly, in contrast to previous reports
which show Her2-dependent Mcl-1 regulation under
normoxic conditions [24, 25, 29], siRNA-mediated
knockdown of the HER2 gene (siHER2) in Her2-positive
BC cells did not affect Mcl-1 protein levels under hyp-
oxic conditions (Fig. 2b). CoCl2 binds to the iron center
of the Hif-specific hydroxylase. It thereby inhibits the
hydroxylation of Hif, its ubiquitination by pVHL, and
proteasomal degradation. In agreement with our hypoth-
esis that Mcl-1 regulates Her2 and downstream Hif-1α
protein levels in BC cells under hypoxic conditions,
treatment with CoCl2 increased Hif-1α protein levels in
a dose-dependent (Fig. 2c) and time-dependent (Fig. 2d)
manner, without changing Mcl-1 or Her2 levels. More-
over, treatment of Her2-positive BC cells but not Her2-
negative BC cells with the Her2 inhibitors trastuzumab
(Fig. 2e) and lapatinib (Fig. 2f ) under hypoxic conditions
induced marked downregulation of Hif-1α, but not Mcl-1.
These data correlated with the induction of cell death, as
evidenced by PARP cleavage (Fig. 2e,f). Importantly, treat-
ment with the pan-caspase inhibitor Z-VAD-FMK abro-
gated PARP cleavage induced by siMCL1, but not the
downregulation of Her2 and Hif-1α in BC cells. These
data exclude a caspase-mediated off-target effect of
siMCL1 on Her2 protein levels (Fig. 2g). Taken together,
these data confirm a role for Mcl-1 upstream of Her2 and
Hif-1α under hypoxic conditions.
The novel small molecule inhibitor EU-5346 specifically
blocks Mcl-1 followed by cell death
Our own and other studies show that blocking the ef-
fects of Mcl-1 is a promising approach to slow tumor
growth, induce apoptosis, and overcome drug resistance
in BC cells, and Her2-positive BC cells in particular.
One approach to target Mcl-1 functions is the inhibition
of its interaction with pro-apoptotic oncogenes of the
Bcl-2 family. Using ultrahigh-throughput screening of
315,000 compounds coupled with the hit optimization
strategy, the hydroxyquinoline-derived, small molecule
EU-5346 (also ML311; Eutropics Pharmaceuticals, Cam-
bridge, MA, USA) was identified as a potent inhibitor of
Mcl-1/Bim interaction that shows selective activity
against Mcl-1 primed cells [39]. In contrast, only the
Bcl-2-specific BH3-mimetic navitoclax but not EU-5346
caused cell death in highly primed Bcl-2 cells [40]. Our
own results demonstrate that EU-5346 induces apoptosis
in Mcl-1wt/wt but not in Mcl-1Δ/null MEFs (Fig. 3a).
Moreover, EU-5346 induced cell death in Bcl-2/Bcl-xL
double knockout cells that were established as having
Mcl-1 as the dependent anti-apoptotic Bcl-2 family
protein [40]. Having verified the presence of Bcl-2
(Additional file 1: Figure S2a), the potent and highly select-
ive Bcl-2 inhibitor ABT-199 [41] induced apoptosis in both
Mcl-1wt/wt and Mcl-1Δ/null MEFs (Fig. 3b). These data
indicate the specificity of EU-5346 against Mcl-1. Similar
to siRNA-mediated knockdown of Mcl-1, EU-5346 in-
duced marked downregulation of Her2 and Hif-1α in
SKBR3 BC cells followed by cell death, as evidenced by
PARP cleavage (Fig. 3c) and inhibition of [3H]-thymidine
uptake (Fig. 3d). Treatment with the pan-caspase inhibitor
Z-VAD-FMK abrogated PARP cleavage induced by EU-
5346-mediated inhibition of Mcl-1, but not the downregu-
lation of Her2 and Hif-1α in BC cells (Fig. 3c). Moreover,
semiquantitative reverse transcription PCR did not show
EU-5346-induced changes of mRNA levels of Mcl-1, sup-
porting its role as a BH3-mimetic (Additional file 1: Figure
S2b). Taken together these data strongly indicate a role for
EU-5346 as a specific inhibitor of Mcl-1 in Her2-positive
BC cells.
Her2 co-localizes with Mcl-1 within the mitochondrial
fraction
To further support the proposed functional interrelation
of Mcl-1 and Her2, we next explored whether Mcl-1 in-
teracts with Her2 under hypoxic conditions. It is well
established that Her2 localizes to the cell membrane
where it phosphorylates downstream substrates on their
tyrosine residues in response to extracellular stimulation.
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Surprisingly, recent studies found that Her2 also local-
izes to the mitochondrial fraction of BC cells, where it
promotes resistance to hypoxia and E-twenty-six (ETS)
transcription factor inhibitors [42]. We therefore next
sought to investigate whether Her2 and Mcl-1 colocalize






Fig. 2 Mcl-1 is an upstream regulator of Her2 under hypoxic conditions. a Genetic depletion of Mcl-1 in Her2-positive BC cells promotes downregulation
of Her2 and Hif-1α followed by inhibition of BC cell survival. b Mcl-1 protein levels do not decrease after genetically downregulating Her2. a, b BC cells
were transfected with siMCL1 a or siHER2 b for 2 days and then exposed to hypoxia for 6 hours. c, d CoCl2-mediated stabilization of
Hif-1α does not alter Mcl-1 or Her2 levels. BT-474 cells were exposed to CoCl2with indicated doses for 24 hours c and 100 μM CoCl2 for the indicated
time periods d. e, f Pharmacologically targeting Her2 decreases Hif-1α but not Mcl-1 protein levels. BC cells were treated with the indicated doses of
trastuzumab e or lapatinib f for 2 days and then exposed to hypoxia for 6 hours. g siMCL1-induced downregulation of Her2 and Hif-1α is not triggered
by caspase-mediated off-target effects of MCL1 siRNA. Her2-positive BC cells were transfected with siMCL1 for 2 days and then exposed to hypoxia for
6 hours. ZVAD (50 μM) was added 24 hours before collecting samples. a–g Whole-cell extracts were analyzed by immunoblotting with indicated
antibodies. Immunoblotting for Erk2 confirmed equal protein loading. Erk2 extracellular signal-regulated kinase 2, Her2 human epidermal
growth factor receptor 2, Hif hypoxia-inducible factor, kD kilodalton, Mcl-1 myeloid cell leukemia-1, PARP Poly (ADP-ribose) polymerase
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analysis our results show colocalization of Mcl-1 and
Her2 in the mitochondrial fraction. Probing of western
blot membranes with antibodies against prohibitin-1 and
α-tubulin secured the high purity of the mitochondrial
fraction (Fig. 4a).
Importantly, our results show that Mcl-1 coimmu-
noprecipitates with Her2 (Fig. 4b) and that Mcl-1 in-
creases the stability of Her2 by modulating the Her2
protein degradation mechanism. Increased ubiquitina-
tion of Her2 was more pronounced in siMCL1-treated
(data not shown) and EU-5346-treated BC cells than
in control cells (Fig. 4b). Receptor internalization is
often associated with receptor ubiquitination and
targeting to proteasomes for degradation [43]. Indeed,
besides increased Her2 ubiquitination, treatment of
SKBR3 cells with EU-5346 (Fig. 4b) as well as
siMCL1 (data not shown) resulted in the formation of
a 125–130 kD fragment of Her2 that was associated
with a reduction in full-length Her2.
Taking these results together, the specific Mcl-1
inhibitor EU-5346 decreases Her2 protein levels.
Functionally, our data show that the interaction of
Mcl-1 and Her2 mediates protection of Her2 ubi-
quitination and subsequent degradation. Conversely,
blockade of Mcl-1 activity increases Her2 ubiquitina-
tion and degradation.
Fig. 3 The novel small molecule inhibitor EU-5346 specifically blocks Mcl-1 followed by cell death. a, b EU-5346 induces apoptosis in Mcl-1wt/wt
but not Mcl-1Δ/null MEFs a. In contrast, ABT-199 induces apoptosis in both Mcl-1wt/wt and Mcl-1Δ/null MEFs b. MEFs were treated with indicated
concentrations of EU-5346 a or ABT-199 b for 72 hours prior to Annexin V and PI staining. Data represent mean ± SD for triplicate samples. Results
shown are representative of three independent experiments. c EU-5346-induced downregulation of Her2 and associated cell death are not triggered
by caspase-mediated off-target effects of Mcl-1 siRNA. Her2-positive BC (SKBR3) cells were treated with EU-5346 and/or ZVAD (50 μM) and
exposed to hypoxia during the last 6 hours. d EU-5346 inhibits proliferation of Her2-positive BC cells in a dose-dependent manner. BC
cells were treated with EU-5346 for 3 days under hypoxic conditions. [3H]-thymidine was added during the last 8 hours. Data represent
mean ± SD for triplicate samples. Results shown are representative of three independent experiments. c, d Whole-cell extracts were analyzed by
immunoblotting with indicated antibodies. Immunoblotting for Erk2 confirmed equal protein loading. Erk2 extracellular signal-regulated
kinase 2, Her2 human epidermal growth factor receptor 2, Hif hypoxia-inducible factor, kD kilodalton, Mcl-1 myeloid cell leukemia-1, MEF
murine embryonic fibroblast, PARP Poly (ADP-ribose) polymerase
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Synergistic effects of combining trastuzumab with Mcl-1-
targeting approaches in trastuzumab-sensitive Her2-
positive BC cells
In Her2 inhibitor-sensitive Her2-positive BC cells, siMCL1
induced significantly higher rates of cell death when
compared with siHER2, indicating the existence of Mcl-1-
dependent survival pathways in Her2-positive BC cells,
which are independent of the Mcl-1–Her2 axis (Fig. 5a).
In agreement with these data, siMCL1 significantly re-
duced spheroid formation in both BT-474 (Fig. 5b) and
a b
Fig. 4 Her2 colocalizes with Mcl-1 within the mitochondrial fraction. a Mcl-1 and Her2 colocalize within the mitochondrial fraction. Mitochondrial
and cytosolic proteins were isolated using the Qproteome Mitochondria Isolation Kit (Qiagen) according to the manufacturer’s instructions and
analyzed by immunoblotting with indicated antibodies. Anti-Prohibitin 1 was used as a mitochondrial marker and anti-tubulin was used as a
cytoplasmic marker. BC cells were exposed to hypoxia for 6 hours. b EU-5346 induces ubiquitination of Mcl-1-bound Her2. SKBR3 cells were
treated with EU-5346 for 3 days and exposed to hypoxia during the last 6 hours. Whole-cell extracts were immunoprecipitated (IP) with either
Mcl-1 antibody or trastuzumab and analyzed by immunoblotting with indicated antibodies. Nonspecific protein binding and detection were excluded
by incubating protein A-Sepharose beads with lysis buffer and Mcl-1 antibody only (left panel). Input (right panel). C control, Erk2 extracellular
signal-regulated kinase 2, Her2 human epidermal growth factor receptor 2, IgH heavy chain, kD kilodalton, Mcl-1 myeloid cell leukemia-1
Fig. 5 Synergistic effects of combining trastuzumab with Mcl-1-targeting approaches in trastuzumab-sensitive Her2-positive BC cells. a Genetic
depletion of Mcl-1 or Her2 induces cell death in Her2-positive BC cells, but not benign breast cells (MCF-10A). BC and MCF-10A cells were
transfected with siMCL1 (filled bars) or siHER2 (open bars) for 30 hours and then exposed to hypoxia for 2 days. Cell survival was determined by
AlamarBlue® assay. Data represent mean ± SD for triplicate samples. Results shown are representative of three independent experiments. b Synergistic
effects of combining trastuzumab with siMCL1 in Her2-positive BC cells. BT-474 cells (5.5 × 103 cells) were seeded per well in agar-coated 96-well plates
prior to siMCL1 transfection. Spheroid formation was assessed in siMCL1-treated and/or trastuzumab-treated and control cells using an inverted fluores-
cence light microscope. Photographs (10× magnification) of spheroid formation are representative of each group and three independent exper-
iments (left). Spheroid volumes were calculated as described in Materials and methods. Data represent mean ± SD (right). c Synergistic growth
inhibition of trastuzumab and EU-5346 in trastuzumab-sensitive Her2-positive BC cells under hypoxic conditions. BT-474 cells were pretreated with tras-
tuzumab or dimethyl sulfoxide (DMSO) for 24 hours under normoxic conditions followed by EU-5346 treatment or DMSO for 72 hours under
hypoxic conditions. [3H]-thymidine was added during the last 8 hours. Data represent mean ± SD for triplicate samples. Results shown are represen-
tative of three independent experiments. Trastuzumab (white bars), EU-5346 (gray bars), and drug combination (black bars). Combination index (CI) was
calculated using the Combosyn software as described in Materials and methods. a, b *p <0.05 and **p <0.001 by Student’s t test
Bashari et al. Breast Cancer Research  (2016) 18:26 Page 9 of 15
SKBR3 (data not shown) cells. Moreover, the combination
therapy of trastuzumab with EU-5346 synergistically trig-
gered cell death in BT-474 (Fig. 5c), as determined by
[3H]-thymidine uptake and subsequent analysis according
to the Chou-Talalay method.
Taken together, our results indicate the existence of
Mcl-1-dependent survival pathways in Her2-positive BC
cells, which are independent of the Mcl-1–Her2 axis;
and support the therapeutic benefit of combining Her2
and Mcl-1 inhibitors.
Genetically and pharmacologically targeting Mcl-1 induces
cell death also in trastuzumab-resistant Her2-positive BC
cells
All Her2-positive BC patients eventually develop resist-
ance to trastuzumab and other Her2 inhibitors. The pre-
cise mechanism of resistance against these inhibitors
remains elusive. We next investigated whether genetic-
ally and pharmacologically targeting Mcl-1 is also active
in trastuzumab-resistant HCC-1954 cells. Similar to
trastuzumab-sensitive BT-474 and SKBR3 BC cells
(Figs. 2 and 3), both siMCL1 and EU-5346 treatment in-
duced cell death in HCC-1954 cells, as evidenced by the
induction of PARP cleavage (Fig. 6a), inhibition of [3H]-
thymidine uptake (Fig. 6b), and inhibition of spheroid for-
mation (Fig. 6c, d). As expected, in contrast to BT-474
cells no synergistic effects of combining trastuzumab with
siMCL1 (Fig. 6d) or EU-5346 (data not shown) were ob-
served on spheroid formation (Fig. 6d) or [3H]-thymidine
uptake followed by the Cou-Talalay analysis (data not
shown). Similar results were obtained in primary BC cells
isolated from a patient with advanced disease and resistant
against multiple agents including Her2 inhibitors, capecit-
abine, paclitaxel, eribulin, and everolimus. Specifically,
siMCL1 (Fig. 6e) and EU-5346 (Fig. 6f,g) but not siHER2
(Fig. 6e) induced cell death as evidenced by PARP cleavage
(Fig. 6e,f) and dose-dependent inhibition of [3H]-thymi-
dine uptake (Fig. 6g).
Taken together these data demonstrate that targeting
Mcl-1 has therapeutic potential not only in Her2 inhibitor-
sensitive but also in Her2 inhibitor-resistant BC cells.
Genetically and pharmacologically targeting Mcl-1 induces
cell death in brain-primed Her2 inhibitor-resistant
Her2-positive BC cells
Brain metastasis is an end stage in BC progression.
Compared with hormone receptor (HR)-positive BC pa-
tients, Her2-positive BC patients show a high incidence
of brain metastasis of more than 20 % [44], with an
overall survival of 4-6 months with whole brain radio-
therapy to about 18 months with multimodal therapies
[45]. Although trastuzumab is effective for systemic BC,
its efficacy in brain metastasis remains controversial
[46]. Moreover, the incidence of brain metastatic disease
after adjuvant trastuzumab is increasing with the im-
proved management of systemic disease and prolonga-
tion of survival [11, 47]. We next sought to investigate
the anti-BC activity of targeting Mcl-1 in brain-primed
(JIMT-1BR3) versus maternal Her2 JIMT-1 cells. Our
data demonstrate marked downregulation of Her2 and
Hif-1α in both JIMT-1 and JIMT-1BR3 cells after
siRNA-mediated Mcl-1 downregulation (Fig. 7a). More-
over, silencing of Mcl-1 induced cell death as evidenced
by PARP cleavage (Fig. 7a), and AlamarBlue® assay
(Fig. 7b). Importantly, similar to maternal JIMT-1 cells,
EU-5346 but not trastuzumab and lapatinib induced cell
death in brain-primed JIMT-1 BR3 cells, as evidenced by
PARP cleavage (Fig. 7c) and [3H]-thymidine uptake
(Fig. 7d). Taken together, these data indicate a thera-
peutic role of targeting Mcl-1 in BC brain metastasis.
Discussion
The present study demonstrates a critical role of Mcl-1
predominantly in Her2-positive BC cell survival and pro-
liferation under hypoxic conditions. Under normoxic con-
ditions, Her2 regulates Mcl-1 upregulation. Conversely,
trastuzumab treatment reduces Mcl-1 levels and renders
cells sensitive to chemotherapy [29]. Surprisingly, in con-
trast to normoxia our data demonstrate a role for Mcl-1
upstream of Her2 in BC cells under hypoxic conditions.
Functionally, we show that under hypoxic conditions
Her2 is detected also in the mitochondrial fraction, where
it binds Mcl-1, strongly indicating a functional interrela-
tion of these two proteins in BC pathogenesis.
To date, therapeutic BH3 mimetics that abrogate anti-
apoptotic activity have been predominantly developed to
target Bcl-2 and Bcl-xL. They function by slotting into
the hydrophobic groove on the surface of Bcl-2 and Bcl-
xL, thereby blocking their capacity to inhibit apoptosis
[48]. Based on their promising preclinical activities, Bcl-
2/Bcl-xL inhibitor ABT-737 [48] and its oral derivate
navitoclax/ABT-263 [49], as well as the highly selective
Bcl-2 inhibitor ABT-199 [41], are currently validated in
advanced clinical trials in solid tumors, acute myeloid
leukemia (AML), chronic lymphocytic leukemia (CLL),
and non-Hodgkin lymphoma (NHL) (https://clinical-
trials.gov). Similar to previous data, our own results
show consistently high Mcl-1 but variable Bcl-2 and Bcl-
xL protein levels in cell lines of different BC subtypes. It
is therefore clear that inhibitors of Mcl-1 hold great
promise as a new class of targeting agents and are the
current focus of widespread cancer drug development ef-
forts. However, the clinical development of Mcl-1 inhibi-
tors has been challenged by structural differences between
the BH3-binding grooves of Mcl-1 and Bcl-2. Indeed, be-
cause of low affinities, ABT-737, navitoclax, and ABT-199
do not block Mcl-1 activity [28, 48, 49]. The high interest
towards the identification of Mcl-1 inhibitors has resulted
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in the recent development of several small molecule BH3
mimetics, which disrupt Mcl-1 function with higher
affinity and overcome resistance to available Bcl-2 family
inhibitors [30, 50]. To date there are no viable clinical can-
didates. Here we evaluated the novel hydroxychinoline-
derived small molecule inhibitor EU-5346 for its activity
in Her2-positive BC cells under hypoxic conditions. Our
data demonstrate EU-5346-induced cell death of Her2-
positive BC cells and that Mcl-1 is required for cell killing.
In addition we have found that, functionally, EU-5346
triggers ubiquitination of Mcl-1-bound Her2, indicating a





Fig. 6 Genetically and pharmacologically targeting Mcl-1 induces cell death also in trastuzumab-resistant Her2-positive BC cells. a Both genetic
depletion of Mcl-1 (siMCL1) and EU-5346 induces apoptosis in trastuzumab-resistant HCC-1954 BC cells. BC cells were transfected with siMCL1 (left)
for 2 days or treated with EU-5346 (right) for 3 days and then exposed to hypoxia for 6 hours. b EU-5346 inhibits proliferation in Her2 inhibitor-
sensitive and inhibitor-resistant BC cells in a dose-dependent manner. c EU-5346 inhibits spheroid formation in both trastuzumab-sensitive (BT-
474) and trastuzumab-resistant (HCC-1954) BC cells. d Combining trastuzumab with siMCL1 in Her2 inhibitor-resistant Her2-positive BC cells does
not induce synergistic effects. HCC-1954 cells (5.5 × 103 cells) were seeded per well in agar-coated 96-well plates prior to siMCL1 transfection. c, d
Spheroid formation was assessed in EU-5346-treated or siMCL1-treated and/or trastuzumab-treated and control cells using an inverted fluores-
cence light microscope. Photographs of spheroid formation (10× magnification) are representative of each group and three independent
experiments (left). Spheroid volumes were calculated as described in Materials and methods. Data represent mean ± SD (right). *p <0.05
and **p < 0.001 by Student’s t test. e, f siMCL1 e and EU-5346 f but not siHER2 e induces apoptosis in multidrug/Her2 inhibitor-
resistant patient BC cells. BC cells were transfected with siMCL1 or siHER2 e for 2 days or treated with EU-5346 f for 3 days and then ex-
posed to hypoxia for 6 hours. a, e, f Whole-cell extracts were analyzed by immunoblotting with indicated antibodies. Immunoblotting for Erk2
confirmed equal protein loading. g EU-5346 inhibits proliferation in multidrug/Her2 inhibitor-resistant patient BC cells in a dose-dependent
manner. b, g BC cells were treated with EU-5346 for 3 days under hypoxic conditions. [3H]-thymidine was added during the last 8 hours. Data
represent mean ± SD for triplicate samples. Results shown are representative of three independent experiments. Erk2 extracellular signal-regulated
kinase 2, Her2 human epidermal growth factor receptor 2, Hif hypoxia-inducible factor, kD kilodalton, Mcl-1 myeloid cell leukemia-1, PARP Poly (ADP-ribose)
polymerase
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protein levels. Studies which delineate detailed molecular
mechanisms by which Mcl-1 protects Her2 against ubi-
quitination and concomitant degradation are currently
ongoing. In addition to Mcl-1/Her2-dependent survival
pathways, our results indicate the existence of Mcl-1-
dependent survival pathways in Her2-positive BC cells,
which are independent of the Mcl-1–Her2 axis (Fig. 8).
Importantly, siRNA-mediated knockdown of Mcl-1 and
EU-5346 induced cell death also in BC cell lines resistant
against Her2 inhibitors, trastuzumab and lapatinib in par-
ticular (Fig. 8); as well as in brain-primed Her2-positive
BC cells resistant to Her2 inhibitors.
Mcl-1 mediates inherent resistance against widely used
anticancer therapies including paclitaxel [26] and gemci-
tabine [27], as well as BH3 mimetics. Moreover, Mcl-1
may also contribute to the acquired resistance to specific
BH-3 mimetics [51]. Silencing of Mcl-1 resensitized
tumor cells to ABT-737 and decreased their resistance
to anoikis [52, 53]. Owing to their functional redun-
dancy, pan-active Bcl-2 inhibitors with at least some ac-
tivity against Mcl-1 or the combination of Mcl-1 with
other Bcl-2/Bcl-xL inhibitors are likely to achieve higher
response rates than targeting one individual member of
the Bcl-2 subfamily.
The use of multiprotein indexes has been proposed to
predict response rates to single-agent Mcl-1 inhibitors
or their combination with other inhibitors of the Bcl-2
family [54, 55]. However, in vivo studies are needed to
confirm the utility of these indexes. Currently we are
evaluating the in vitro anti-BC activity of EU-5346 in
combination with ABT-199, and navitoclax, as well as
with paclitaxel and gemcitabine.
Finally, our own and other data demonstrate high Mcl-1
protein levels also in Her2-negative BC cells, Luminal A-
like BC and TNBCs in particular [25, 55–57]. Based on
this protein profile, we evaluated whether siMCL1 and
EU-5346 induce cell death also in these BC subtypes.
Indeed, our results demonstrate anti-BC activity in
Luminal A-like (MCF-7) and TNBC (MDA MB-231)
cells upon both siRNA-mediated downregulation of
Mcl-1 (Additional file 1: Figure S3a,b) as well as treatment
with EU-5346 (Additional file 1: Figure S3c,d), as evi-
denced by PARP cleavage (Additional file 1: Figure S3a,c),




Fig. 7 Genetically and pharmacologically targeting Mcl-1 induces cell death in brain-primed Her2 inhibitor-resistant Her2-positive BC cells.
a, b Genetic depletion of Mcl-1 induces apoptosis in both maternal Her2 inhibitor-resistant Her2-positive JIMT-1 cells as well as in brain-primed JIMT-1
BR3 cells. a BC cells were transfected with siMCL1 for 2 days and exposed to hypoxia for 6 hours. Whole-cell extracts were analyzed by immunoblotting
with indicated antibodies. Immunoblotting for Erk2 confirmed equal protein loading. b BC cells were transfected with siMCL1 for 30 hours and then
exposed to hypoxia for 2 days. Cell survival was determined by AlamarBlue® assay. Data represent mean ± SD for triplicate samples. Results
shown are representative of three independent experiments. c EU-5346 overcomes Her2 inhibitor resistance in brain-primed Her2-positive BC cells. BC
cells were treated with indicated drugs for 3 days and then exposed to hypoxia during the last 6 hours. Whole-cell extracts were analyzed by
immunoblotting with indicated antibodies. Immunoblotting for Erk2 confirmed equal protein loading. d EU-5346 inhibits proliferation of brain-
primed Her2-positive BC cells in a dose-dependent manner. BC cells were treated with EU-5346 for 3 days under hypoxic conditions. [3H]-
thymidine was added during the last 8 hours. Data represent mean ± SD for triplicate samples. Results shown are representative of three
independent experiments. C control (dimethyl sulfoxide), E EU-5346, Erk2 extracellular signal-regulated kinase 2, Her2 human epidermal
growth factor receptor 2, Hif hypoxia-inducible factor, kD kilodalton, L lapatinib, Mcl-1 myeloid cell leukemia-1, T trastuzumab
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[3H]-thymidine uptake (Additional file 1: Figure S3d).
Molecular mechanisms by which Mcl-1 induces cell
death in these BC subtypes need to be further explored
(Additional file 1: Figure S3e). Importantly, Balko et al.
[58] recently demonstrated that TNBC cells residual after
neoadjuvant chemotherapy express high levels of Mcl-1;
and that Mcl-1 protects TNBCs from chemotherapy-
induced apoptosis. These data support a therapeutic role
of targeting Mcl-1 also in TNBC cells. Future investiga-
tions into whether a similar role for Mcl-1 also exists in
other BC subtypes are of high interest.
Conclusion
In summary, the present study adds another facet to the
critical pathophysiologic role of Mcl-1 in BC pathogen-
esis in general, and Her2-positive BC cells in particular.
The study thereby supports the clinical development of
therapies, which target Mcl-1 alone or in combination
with other therapies, both under normoxic and hypoxic
conditions in order to further improve patient outcome
in BC.
Additional file
Additional file 1: Figure S1. Showing MCL-1 mRNA levels do not
change in Her2-positive BC cells under hypoxic conditions. Figure S2
showing a Bcl-2 is expressed in both Mcl-1wt/wt and Mcl-1Δ/null MEFs.
Whole-cell extracts were analyzed by immunoblotting with indicated
antibodies. Immunoblotting for Erk2 confirmed equal protein loading.
b EU-5346 does not change Mcl-1 mRNA expression in Her2-positive BC
cells under hypoxic conditions. Figure S3 showing Mcl-1 is a potential
therapeutic target not only in Her2-positive, but also in Luminal A-like
and TNBC cells under hypoxic conditions. (PDF 1580 kb)
Fig. 8 Summary: Mcl-1 confers protection of Her2-positive BC cells to hypoxia—therapeutic implications. Homodimerization of Her2 with Her2 or
heterodimerization of Her2 with Her3 enhances phospho-inositol 3-kinase (PI3K)/AKT and RAS/mitogen-activated protein kinase (MAPK) pathways,
which regulate BC cell proliferation, survival, and migration, as well as angiogenesis [60, 61]. The Her2 inhibitor trastuzumab [62] binds to the C-
terminal portion of Her2. Another Her2 inhibitor, lapatinib [63], binds to the ATP binding site of Her2, but also Her1. Similar to siHER2, trastuzumab
and lapatinib inhibit downstream signaling events, induce apoptosis, and inhibit proliferation of BC cells (red lines). Here we show a novel role for
the antiapoptotic Bcl-2 family member Mcl-1 in Her2-positive BC cell adaptation to hypoxia. Specifically, our results show that Mcl-1 forms
a protein complex with Her2 at the mitochondrial membrane and stabilizes Her2 by inhibiting its ubiquitination. Conversely, genetically
(siMCL1) or pharmacologically (EU-5346) targeting Mcl-1 triggers ubiquitination and proteosomal degradation of Her2, thereby inducing apoptosis, and
inhibiting proliferation and spheroid formation under hypoxic conditions. In addition, our results indicate the existence of a Mcl-1-dependent
survival pathway in Her2-positive BC cells, which is independent of the Mcl-1–Her2 axis supporting the therapeutic benefit of combining Her2 (red lines)
and Mcl-1 inhibitor (blue lines). Importantly, based on these findings, targeting Mcl-1 is also active in Her2-positive BC cells resistant to Her2 inhibitors,
including a brain-primed Her2-positive cell line. Her human epidermal growth factor receptor, Mcl-1 myeloid cell leukemia-1. (Color figure online)
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